Xiaolong Huang et al. aiming at targeting a variety of subsets of cancer-initiating cells, developed CD133 [92] and CD44 [93] aptamer-conjugated nanomicelles loaded with gefitinib (CD133/CD44–NM–Gef) to target CD133+ and CD44+ lung cancer-initiating cells (Figure 5a). This evidence concerns the gene CD44 and cancer.